Sonoma Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

10. Significant Customer Concentrations

10. Significant Customer Concentrations	3 Months Ended
Jun. 30, 2014
Significant Customer Concentrations
10. Significant Customer Concentrations	For the three months ended June 30, 2014, one customer represented 43%, and one customer represented 16% of the quarter’s revenue. For the three months ended June 30, 2013, one customer represented 42%, and one customer represented 22% of the quarter’s revenue. At June 30, 2014, one customer represented 36%, and one customer represented 16%, and two customers each represented 15% of the net accounts receivable balance. At March 31, 2014, one customer represented 44%, one customer represented 15%, and one customer represented 12% of the net accounts receivable balance.

10. Significant Customer Concentrations

3 Months Ended

Jun. 30, 2014

For the three months ended June 30, 2014, one customer represented 43%, and one customer represented 16% of the quarter’s revenue.

For the three months ended June 30, 2013, one customer represented 42%, and one customer represented 22% of the quarter’s revenue.

At June 30, 2014, one customer represented 36%, and one customer represented 16%, and two customers each represented 15% of the net accounts receivable balance. At March 31, 2014, one customer represented 44%, one customer represented 15%, and one customer represented 12% of the net accounts receivable balance.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References + Details